Key facts
- ZBiotics’s last known valuation is $67.0M (Aug 2024).
- It has raised $40.3M across 2 recorded rounds; the latest was Early Stage VC ($22.4M) in Mar 2024.
- Notable investors include Plug and Play Tech Center, Y Combinator, FJ Labs, Pareto Holdings, Kevin Moore — 34 tracked in total.
- ZBiotics has filed 2 Form Ds with the SEC since 2020, most recently Apr 2024 ($22.4M sold to 68 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 34 names
- ·Watchlist + deal alerts for ZBiotics
Funding rounds
2 roundsAbout ZBiotics
Developer of genetically engineered probiotics designed to improve the body's ability to break down unwanted byproducts of alcohol to convert sugar into fiber in the gut. The company offers a probiotic drink that breaks down acetaldehyde, an undesirable byproduct of alcohol, enabling users to prevent the worst next-day effects of drinking.
- Sector
- Consumer Products and Services (B2C)
- HQ
- San Francisco, CA, United States
- Founded
- 2016
- Employees
- 48
- Website
- zbiotics.com/
- Ownership
- Privately Held (backing)
ZBiotics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ZBiotics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ZBiotics in its N-PORT filings yet. We sweep new filings monthly.